Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

2.135 -0.065 (-2.95%)
Streaming Delayed Price Updated: 1:34 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eledon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
David-Alexandre (‘DA’) Gros, CEO of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), to Present at NobleCon20
Via Investor Brand Network
News headline image
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Enrollment Completed Four Months Ahead of Schedule 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.